Flying high on obesity success, Novo's appetite for partnerships grows https://ift.tt/O95rNv3

John McDonald, corporate vice president of global R&D business development, said the Danish drugmaker aims to shed its image of being a company that tends to "window shop", but hardly ever presses the trigger on deals. Its interest is largely in areas it has already invested in, including diabetes, obesity, cardiovascular disease and gene therapies, he said on a panel at the LSX World Congress conference.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ZbfmwHy